Youcare Pharmaceutical’s YKYY033 siRNA Injection Wins US FDA Approval to Conduct Clinical Trials for Arterial and Venous Thrombosis
Youcare Pharmaceutical (SHA: 688658) announced that YKYY033 injection has received approval from the US Food...
AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab
AstraZeneca plc (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that a new indication for...
Hengrui Pharma’s SHR-7590 Injection Wins NMPA Clinical Trial Approval for Ulcerative Colitis and Crohn’s Disease
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its SHR-7590 injection has...
Zhaoke Ophthalmology Signs Exclusive Distribution and Promotion Agreement With Pengpai Bio for Epinastine Hydrochloride Eye Drops in Mainland China
Zhaoke Ophthalmology (HKG: 6622) announced that it has entered into an exclusive distribution and promotion...
IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform
IMPACT Therapeutics, Inc. (HKG: 7630) announced the nomination of IMP2794 as a preclinical candidate (PCC)...
Akeso’s Ivonescimab Wins NMPA Approval for First-Line Advanced Squamous Non-Small Cell Lung Cancer in Combination With Chemotherapy
Akeso Biopharma (HKG: 9926) announced that the National Medical Products Administration (NMPA) of China has...
Allist Pharmaceuticals Secures Exclusive Greater China License for ArriVent’s Bispecific ADC AST12608/ARR-002
Allist Pharmaceuticals (SHA: 688578) announced that it has signed a strategic collaboration agreement with ArriVent...
Kintor Pharmaceutical Grants Wellrise Exclusive Distribution Rights for KT-939 Raw Material in South Korea
Kintor Pharmaceutical (HKG: 9939) announced that it has entered into an exclusive product distribution agreement...
CSPC Pharmaceutical Receives $30 Million Upfront From AstraZeneca Under siRNA Drug Discovery Partnership
CSPC Pharmaceutical Group (HKG: 1093) announced that it has received a USD 30 million upfront...
Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal
Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced that the New Drug Application (NDA) for...
NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib
The National Medical Products Administration (NMPA) approved Geneseeq Technology Inc.‘s (a genetic cancer testing service...
Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million
Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of a Series...
Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026
Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral...
Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism
Shanghai Haohai Biological Technology Co. Ltd. (SHA: 688366) announced that its trifocal toric intraocular lens...
Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its self‑developed 9‑valent human...
Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that it has entered into...
MSD Signs Oncology Collaboration With InventisBio Through MCICC to Accelerate Small‑Molecule Clinical Development
Merck & Co., Inc. (MSD; NYSE: MRK) announced that it has signed a collaboration agreement...
Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Guangzhou Baiyunshan Xihe Health Medicine Co., Ltd. announced the...
IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million
IMPACT Therapeutics, Inc. (HKG: 7630) announced an exclusive partnership with Pharmanovia for senaparib (brand name:...
Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia
Essex Bio-Technology (HKG: 1061) announced a strategic collaboration framework agreement with Gunze Medical Limited to...